Evidence map›Paper›PMID 25150735›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2014

The Israel Diabetes and Cognitive Decline (IDCD) study: Design and baseline characteristics.

Michal Schnaider Beeri, Ramit Ravona-Springer, Erin Moshier, James Schmeidler, James Godbold, Tomas Karpati, Derek Leroith, Keren Koifman, Efrat Kravitz, Rachel Price and 3 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
Open the trial in the graph
NCT02832921 naunknown statusnot on this mapstarted 2016, after this paper: background citation

Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk

TypeinterventionalSponsorSheba Medical CenterRan2016 to 2019Enrolled200ConditionsAlzheimer's Disease (AD)Armscognitive training by virtual reality, watching a scientific TV documentary, treadmill
3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Computerized Cognitive Training for Older Adults at Higher Dementia Risk due to Diabetes: Findings From a Randomized Controlled Trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2020 · on this map
    Trial
  2. Article
  3. Emotional response to amyloid beta status disclosure among research participants at high dementia risk.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Consumption of Ultra-Processed Food and Cognitive Decline among Older Adults With Type-2 Diabetes.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
    Article
  11. Article
  12. Stability in BMI over time is associated with a better cognitive trajectory in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Increase in Number of Depression Symptoms Over Time is Related to Worse Cognitive Outcomes in Older Adults With Type 2 Diabetes.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michal Schnaider BeeriDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Department of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel. Electronic address: michal.beeri@mssm.edu.
Ramit Ravona-SpringerDepartment of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel.
Erin MoshierDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA.
James SchmeidlerDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA.
James GodboldDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Tomas KarpatiMaccabi Healthcare Services, Israel.
Derek LeroithDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Keren KoifmanDepartment of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel.
Efrat KravitzDepartment of Psychiatry, Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel-Aviv, Israel.
Rachel PriceMaccabi Healthcare Services, Israel.
Hadas HoffmanMaccabi Healthcare Services, Israel.
Jeremy M SilvermanDepartments of Psychiatry and Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA; Departments of Preventive Medicine, Mount Sinai School of Medicine, New York, NY, USA.
Anthony HeymannMaccabi Healthcare Services, Israel.

Funding

VESICULAR LOCALIZATION AND FUNCTION OF PRESENILIN 1 FRAGMENTP50AG005138 · NIA · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GROSSMAN, HILLEL · 1985 to 2019
$37.9M
Inflammation, long-term diabetes characteristics, and cognitive declineR01AG034087 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL · 2009 to 2014
$3.7M
Long term instability of glycemic control and hippocampal functionR21AG043878 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHNAIDER BEERI, MICHAL · 2014 to 2015
$375k
NIA NIH HHS P50 AG005138NIA NIH HHS P50 AG05138NIA NIH HHS R01 AG034087NIA NIH HHS R21 AG043878
6 · The paper itself

Abstract

backgroundType 2 diabetes (T2D) is associated with increased risk of dementia. The prospective longitudinal Israel Diabetes and Cognitive Decline study aims at identifying T2D-related characteristics associated with cognitive decline.

methodsSubjects are population-based T2D 65+, initially cognitively intact. Medical conditions, blood examinations, and medication use data are since 1998; cognitive, functional, demographic, psychiatric, DNA, and inflammatory marker study assessments were conducted every 18 months. Because the duration of T2D reflects its chronicity and implications, we compared short (0-4.99 years), moderate (5-9.99), and long (10+) duration for the first 897 subjects.

resultsThe long duration group used more T2D medications, had higher glucose, lower glomerular filtration rate, slower walking speed, and poorer cognitive functioning. Duration was not associated with most medical, blood, urine, and vital characteristics.

conclusionsTracking cognition, with face-to-face evaluations, exploiting 15 years of historical detailed computerized, easily accessible, and validated T2D-related characteristics may provide novel insights into T2D-related dementia.

Indexed as

Activities of Daily LivingAgedAged, 80 and overCognition DisordersCommunity Health PlanningDiabetes Mellitus, Type 2FemaleHumansIsraelLongitudinal StudiesMaleNeuropsychological TestsPsychiatric Status Rating ScalesRegistriesCognitive declineCognitively normalDementiaElderlyRisk factorsStudy designType 2 diabetes

Identifiers

PMID25150735
PMCPMC4330555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.